Drug intelligence / Profile preview

nicotine

Development stage
Approved
Lead developer
Pfizer
Modality
Small Molecules
Administration
Buccal, Inhalation, Intranasal, Oral, Sublingual, Transdermal
01

Overview

Nicotine is a naturally occurring alkaloid found in tobacco and other plants of the nightshade family. It is a highly addictive stimulant and the primary psychoactive component responsible for tobacco dependence. Medically, nicotine is used as an aid to smoking cessation and for relief of withdrawal symptoms through various forms of nicotine replacement therapy (NRT), such as patches, gum, lozenges, inhalers, and nasal sprays[1][4]. Mechanistically, nicotine acts primarily as an agonist at nicotinic acetylcholine receptors (nAChRs) in the central and peripheral nervous systems. Activation of these ionotropic receptors leads to neuronal depolarization and increased release of neurotransmitters—most notably dopamine in reward pathways—which underlies its reinforcing effects[1][5][6]. At higher doses or with chronic use it can also have sedative properties. The addictive potential of nicotine makes it one of the most widely abused substances globally[2][8].

Brand names
HabitrolNicoderm C-QNicoreliefNicoretteNicotrol
Other names
Research ENDS S-TA-U001Electronic Nicotine Delivery System S-TA-U001
02

Targets

CHRNA7 (α7 nicotinic receptor)α4β2 nAChR (Nicotinic acetylcholine receptor alpha4 beta2 subtype)

Beyond the preview

Go deeper on nicotine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on nicotine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call